142 related articles for article (PubMed ID: 17206723)
1. Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors.
Hlavaty T; Ferrante M; Henckaerts L; Pierik M; Rutgeerts P; Vermeire S
Inflamm Bowel Dis; 2007 Apr; 13(4):372-9. PubMed ID: 17206723
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study.
Choi CH; Song ID; Kim YH; Koo JS; Kim YS; Kim JS; Kim N; Kim ES; Kim JH; Kim JW; Kim TO; Kim HS; Kim HJ; Park YS; Park DI; Park SJ; Song HJ; Shin SJ; Yang SK; Ye BD; Lee KM; Lee BI; Lee SY; Lee CK; Im JP; Jang BI; Jeon TJ; Cho YK; Chang SK; Jeon SR; Jung SA; Jeen YT; Cha JM; Han DS; Kim WH;
Yonsei Med J; 2016 Nov; 57(6):1376-85. PubMed ID: 27593865
[TBL] [Abstract][Full Text] [Related]
4. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
[TBL] [Abstract][Full Text] [Related]
5. Infliximab use in luminal Crohn's disease.
Richter JA; Bickston SJ
Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
[TBL] [Abstract][Full Text] [Related]
6. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.
Louis E; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Malaise M; Belaiche J
Scand J Gastroenterol; 2002 Jul; 37(7):818-24. PubMed ID: 12190096
[TBL] [Abstract][Full Text] [Related]
7. [Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
Kiss LS; Szamosi T; Molnár T; Miheller P; Lakatos L; Vincze A; Palatka K; Bartha Z; Gasztonyi B; Salamon A; Horváth G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovász BD; Végh Z; Golovics PA; Szathmári M; Papp M; Lakatos PL
Orv Hetil; 2011 Sep; 152(36):1433-42. PubMed ID: 21865144
[TBL] [Abstract][Full Text] [Related]
8. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
Lindsay J; Punekar YS; Morris J; Chung-Faye G
Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea].
Choi KD; Song HJ; Kim JS; Jung HC; Song IS
Korean J Gastroenterol; 2005 Jul; 46(1):48-55. PubMed ID: 16030404
[TBL] [Abstract][Full Text] [Related]
11. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M
Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373
[TBL] [Abstract][Full Text] [Related]
12. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.
Pearce CB; Lawrance IC
J Gastroenterol Hepatol; 2007 Oct; 22(10):1671-7. PubMed ID: 17845695
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
[TBL] [Abstract][Full Text] [Related]
14. Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn's Disease in Children.
El-Matary W; Walters TD; Huynh HQ; deBruyn J; Mack DR; Jacobson K; Sherlock ME; Church P; Wine E; Carroll MW; Benchimol EI; Lawrence S; Griffiths AM
Inflamm Bowel Dis; 2019 Jan; 25(1):150-155. PubMed ID: 29912413
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience.
Sprakes MB; Ford AC; Warren L; Greer D; Hamlin J
J Crohns Colitis; 2012 Mar; 6(2):143-53. PubMed ID: 22325168
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for the efficacy of infliximab in patients with luminal fistulizing Crohn's disease.
Ma Y; Zhang R; Liu W; Sun Y; Li J; Yang H; Lv H; Li Y; Tan B; Sun X; Qian J; Li J
BMC Gastroenterol; 2023 Mar; 23(1):57. PubMed ID: 36890451
[TBL] [Abstract][Full Text] [Related]
17. Infliximab treatment and prognostic factors for response in patients with Crohn's disease.
Mendoza JL; García-Paredes J; Cruz Santamaria DM; Lana R; Ramírez Fernández E; Rodríguez Asteaga E; Díaz-Rubio M
Rev Esp Enferm Dig; 2002 May; 94(5):269-79. PubMed ID: 12474335
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of concomitant elemental diet therapy in scheduled infliximab therapy in patients with Crohn's disease to prevent loss of response.
Kamata N; Oshitani N; Watanabe K; Watanabe K; Hosomi S; Noguchi A; Yukawa T; Yamagami H; Shiba M; Tanigawa T; Watanabe T; Tominaga K; Fujiwara Y; Arakawa T
Dig Dis Sci; 2015 May; 60(5):1382-8. PubMed ID: 25532505
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe--a Hungarian nationwide observational study.
Miheller P; Lakatos PL; Horváth G; Molnár T; Szamosi T; Czeglédi Z; Salamon A; Czimmer J; Rumi G; Palatka K; Papp M; Jakab Z; Szabó A; Gelley A; Lakatos L; Barta Z; Balázs C; Rácz I; Zeher M; Döbrönte Z; Altorjay I; Hunyady B; Simon L; Papp J; Banai J; Nagy F; Lonovics J; Ujszászy L; Muzes G; Herszényi L; Tulassay Z
BMC Gastroenterol; 2009 Sep; 9():66. PubMed ID: 19740450
[TBL] [Abstract][Full Text] [Related]
20. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease.
Taxonera C; Rodrigo L; Casellas F; Calvet X; Gómez-Camacho F; Ginard D; Castro M; Castro L; Ponce M; Martínez-Montiel P; Ricart E; Gisbert JP; López-San Román A; Morales JM; Casado MA
J Clin Gastroenterol; 2009; 43(10):950-6. PubMed ID: 19448569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
